Abstract
An important parameter for COVID-19 is the case fatality rate (CFR). It has been applied to wide applications, including the measure of the severity of the infection, the estimation of the number of infected cases, risk assessment etc. However, there remains a lack of understanding on several aspects of CFR, including population factors that are important to CFR, the apparent discrepancy of CFRs in different countries, and how the age effect comes into play. We analyze the CFRs at two different time snapshots, July 6 and Dec 28, with one during the first wave and the other a second wave of the COVID-19 pandemic. We consider two important population covariates, age and GDP as a proxy for the quality and abundance of public health. Extensive exploratory data analysis leads to some interesting findings. First, there is a clear exponential age effect among different age groups, and, more importantly, the exponential index is almost invariant across countries and time in the pandemic. Second, the roles played by the age and GDP are a little surprising: during the first wave, age is a more significant factor than GDP, while their roles have switched during the second wave of the pandemic, which may be partially explained by the delay in time for the quality and abundance of public health and medical research to factor in.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding received for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work is statistical data analysis, and no human or animal subjects involved.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are public data, available at relevant Worldometer, Wikipedia, or United Nation web. Data will also be shared later at Github.
